Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Growth in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 333,800 shares, a growth of 243.1% from the January 31st total of 97,300 shares. Based on an average trading volume of 1,590,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 6.0% of the shares of the company are sold short.

Tonix Pharmaceuticals Price Performance

NASDAQ TNXP traded down $0.32 during midday trading on Friday, hitting $7.86. The company had a trading volume of 281,927 shares, compared to its average volume of 1,262,109. The company has a market capitalization of $14.69 million, a PE ratio of 0.00 and a beta of 2.07. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $24.99 and a 200-day moving average price of $22.36. Tonix Pharmaceuticals has a twelve month low of $7.54 and a twelve month high of $1,244.16.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating for the company.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Commonwealth Equity Services LLC acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $40,000. Two Sigma Investments LP acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $66,000. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $72,000. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $162,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth $526,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.